EUVIMEDEUVIMED entdecken
Multizentrische Studie

NTRK Fusion Landscape in 195 Positive Cases of 17 Tumors: A Chinese Multicenter Retrospective Study With Optimized Pan-TRK Immunohistochemistry (IHC) Screening

Shafei Wu, Jian Wang, Wentao Yang, Yuchen Han, Zhihong Zhang, Gang Chen, Bin Meng, Yan Sun, Yang Liu, Wencai Li, Shenglei Li, Lifeng Wang und 8 weitere

Modern Pathology · 2026

DOI: 10.1016/j.modpat.2026.101007 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Modern Pathology, 2026. Verfasst von Shafei Wu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Peking Union Medical College Hospital, Beijing, China. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Immunohistochemistry, Neoplasms, Oncogene Proteins, Fusion. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurotrophic tyrosine receptor kinase (NTRK) fusions are crucial in tumorigenesis and in guiding targeted therapy with TRK inhibitors. However, their rarity, fusion heterogeneity, and limitations of conventional pan-TRK immunohistochemistry (IHC) impede accurate clinical detection. This multicenter retrospective study analyzed 374 next-generation sequencing/fluorescence in situ hybridization-validated samples (195 NTRK positive and 179 NTRK negative) collected from 12 Chinese centers to investigate fusion heterogeneity and refine the interpretation of pan-TRK IHC. We developed an amplification protocol by combining the traditional pan-TRK IHC (EPR17341) with the OptiView Amplification Kit and established new interpretation criteria. A total of 40 solid tumor types were included, and 23 unique fusion partners were identified. Papillary thyroid cancer was the most common NTRK-positive tumor (49.74%) and harbored all 3 NTRK subtypes. Among NTRK-positive samples, NTRK3 (74.87%) was the most prevalent subtype, followed by NTRK1 (23.59%). ETS variant transcription factor 6 (ETV6) was the most frequent fusion partner identified in 122 of 195 cases. It was uniquely shared across all 3 NTRK subtypes, with its fusion to NTRK1 being reported for the first time. NTRK1 and NTRK3 exhibited marked fusion partner specificity, with no overlap in their associated partners except for ETV6. The optimized pan-TRK IHC protocol significantly improved staining efficiency by enhancing intensity and clarity. Consequently, the newly established criteria (cytoplasmic intensity ≥1 in ≥50% of tumor cells or any nuclear intensity ≥1) exhibited outstanding detection performance, achieving an overall sensitivity of 94.36% and increasing specificity to 79.89% compared with 60.22% under the conventional protocol. Particularly, the detection sensitivity for NTRK3 fusions was significantly enhanced and reached 95.89%. This study contributes to clarifying NTRK fusion distribution in patients and validates a standardized, sensitive pan-TRK IHC strategy for clinical screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorImmunohistochemistryNeoplasmsOncogene Proteins, FusionReceptor, trkAAdultAgedFemaleHumansMaleMiddle AgedYoung AdultChinaIn Situ Hybridization, FluorescenceReceptor, trkCRetrospective Studies

Stichwörter der Autor:innen

NTRKfusion heterogeneityimmunohistochemistryinterpretation criteriastaining patterns

Substanzen

Biomarkers, TumorNTRK1 protein, humanNTRK3 protein, humanOncogene Proteins, FusionReceptor, trkAReceptor, trkC

Autor:innen und Institutionen

  • Peking Union Medical College Hospital, Beijing, China.
  • Fudan University Shanghai Cancer Center, Shanghai, China.
  • Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
  • Jiangsu Province Hospital, Nanjing, China.
  • Fujian Cancer Hospital, Fuzhou, China.
  • Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Zitieren

APA

Wu, S., Wang, J., Yang, W., Han, Y., Zhang, Z., Chen, G., Meng, B., Sun, Y., Liu, Y., Li, W., Li, S., Wang, L., Zhang, H., Guo, L., Liu, Y., Liu, X., Hong, R., Li, K., Pang, J., & Liang, Z. (2026). NTRK Fusion Landscape in 195 Positive Cases of 17 Tumors: A Chinese Multicenter Retrospective Study With Optimized Pan-TRK Immunohistochemistry (IHC) Screening. Modern Pathology. https://doi.org/10.1016/j.modpat.2026.101007

Vancouver

Wu S, Wang J, Yang W, Han Y, Zhang Z, Chen G, et al. NTRK Fusion Landscape in 195 Positive Cases of 17 Tumors: A Chinese Multicenter Retrospective Study With Optimized Pan-TRK Immunohistochemistry (IHC) Screening. Modern Pathology. 2026. doi:10.1016/j.modpat.2026.101007

BibTeX
@article{Wu2026,
  author = {Wu, Shafei and Wang, Jian and Yang, Wentao and Han, Yuchen and Zhang, Zhihong and Chen, Gang and Meng, Bin and Sun, Yan and Liu, Yang and Li, Wencai and Li, Shenglei and Wang, Lifeng and Zhang, Hongying and Guo, Lingchuan and Liu, Yueping and Liu, Xiaoding and Hong, Ruping and Li, Kaimi and Pang, Junyi and Liang, Zhiyong},
  title = {NTRK Fusion Landscape in 195 Positive Cases of 17 Tumors: A Chinese Multicenter Retrospective Study With Optimized Pan-TRK Immunohistochemistry (IHC) Screening},
  journal = {Modern Pathology},
  year = {2026},
  doi = {10.1016/j.modpat.2026.101007}
}
Kostenlos starten →